5‘-O-Alkyl Ethers of N,2-Substituted Adenosine Derivatives: Partial Agonists for the Adenosine A1 and A3 Receptors-Reference-Cited by-同舟云学术

5‘-O-Alkyl Ethers of N,2-Substituted Adenosine Derivatives: Partial Agonists for the Adenosine A1 and A3 Receptors

Published:2001-07-26 Issue:18 Volume:44 Page:2966-2975
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

van Tilburg Erica W.¹,van der Klein Pieter A. M.¹,von Frijtag Drabbe Künzel Jacobien¹,de Groote Miriam¹,Stannek Christina¹,Lorenzen Anna¹,IJzerman Ad P.¹

Affiliation:

1. Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, P.O. Box 9502, 2300 RA Leiden, The Netherlands, and Institute of Pharmacology, University of Heidelberg, D-69120 Heidelberg, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm001114o

Reference36 articles.

1. Modulation of hepatic glucose production by non-esterified fatty acids in Type 2 (non-insulin-dependent) diabetes mellitus

2. Adenosine receptor ligands: differences with acute versus chronic treatment

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary Metabolites from the Nematode-Trapping Fungus Dactylellina haptotyla YMF1.03409;Microorganisms;2023-11-03

2. Photoactive glycoconjugates with a very large Stokes shift: synthesis, photophysics, and copper(ii) and BSA sensing;Organic & Biomolecular Chemistry;2023

3. Iodine Catalysed Tandem Stereoselective Acetalation‐Glycosylation of Reducing Sugars Using Acetals/Ketals: Application in the Synthesis of Orthogonally Protected Nucleosides;ChemistrySelect;2022-05-02

4. Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary;Journal of Medicinal Chemistry;2021-08-26

5. Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents;Current Pharmaceutical Design;2019-10-03